Calcium dynamics in the failing heart: Restoration by β-adrenergic receptor blockade

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 1 54-1, 2003, Pages

  Plank, David M ^a   Yatani, Atsuko ^c   Ritsu, Honda ^c   Witt, Sandra ^a   Glascock, Betty ^a   Lalli, M Jane ^b   Periasamy, Muthu ^b   Fiset, Celine ^e   Benkusky, Nancy ^d   Valdivia, Héctor H ^d   Sussman, Mark A ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Cardiomyopathy; Dilated; adrenergic receptor antagonists

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; TROPOMODULIN;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM METABOLISM; CONTROLLED STUDY; DRUG ACTIVITY; ENDOPLASMIC RETICULUM; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SODIUM CALCIUM EXCHANGE; TRANSGENIC MOUSE;

EID: 0038677079     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00425.2002     Document Type: Article

References (53)

1. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, Marks AR, and Olson EN. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89: 997-1004, 2001.
2. 2+-ATPase (SERCA2) gene promoter is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. J Mol Cell Cardiol 31:919-926, 1999.
3. sα mouse. J Clin Invest 104: 551-558, 1999.
4. Barrere-Lamaire S, Piot C, Leclercq F, Nargeot J, and Richard S. Facilitation of L-type calcium currents by diastolic depolarization in cardiac cells: impairment in heart failure. Cardiovasc Res 47: 336-349, 2000.
5. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer, 1991.
6. 2+ buffers. In: Methods in Cell Biology, edited by Nuccitelli R. San Diego, CA: Academic, 1994, p. 4-28.
7. Bristow MA. β-Adrenergic receptor blockade in chronic heart failure. Circulation 88: 895-902, 2000.
8. Bueckelmann DL, Nabauer M, and Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85: 1046-1055, 1992.
9. Dash R, Kadambi FJ, Schmidt AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD, Liggett SB, Lorenz JN, Dorn GW, and Kranias EG. Interactions between phospholamban and β-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103: 889-896, 2001.
10. Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, and Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing hearts by gene transfer of SERCA2a. Circulation 100: 2308-2311, 1999.
11. Doi M, Yano M, Kobayashi S, Kohno M, Tokuhisa T, Okuda S, Suetsugu M, Hisamatsu Y, Ohkusa T, Kohno T, Michihiro M, and Matsuzaki M. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation 105: 1374-1379, 2002.
12. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, and Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24:1310-1320, 1994.
13. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064, 1999.
14. Fan QI, Chen B, and Marsh JD. Transcriptional regulation of L-type calcium channel expression in cardiac myocytes. J Mol Cell Cardiol 32: 1841-1849, 2000.
15. 2+ channel antagonists in animal model of dilated cardiomyopathy. Effects of gross morphology, global cardiac function, and twitch force. Circ Res 73: 1077-1089, 1993.
16. Golden KL, Ren J, O'Connor J, Dean A, Dicarlo SE, and Marsh JD. In vivo regulation of Na/Ca exchanger expression by adrenergic effectors. Am J Physiol Heart Circ Physiol 280: H1376-H1382, 2001.
17. Gwathmey JK. Morphological changes associated with furazolidone-induced cardiomyopathy: effects of digoxin and propranolol. J Comp Pathol 104: 33-45, 1991.
18. Gwathmey JK, Copelas L, MacKinnon R, Schoen FJ, Feldman MD, Grossman W, and Morgan JP. Abnormal intracellular calcium handling in myocardium from patients with endstage heart failure. Circ Res 61: 70-76, 1987.
19. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, and Bristow MR. Cellular and molecular remodeling in heart failure model treated with β-blocker carteolol. Am J Physiol Heart Circ Physiol 276: H1678-H1690, 1999.
20. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, and Rockman HA. Cardiac βARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 97: 5809-5814, 2001.
21. Harrison SM and Bers DM. Correction of proton and calcium association constants of EGTA for temperature and ionic strength. Am J Physiol Cell Physiol 256: C1250-C1256, 1989.
22. 2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation 99: 641-648, 1999.
23. Houser SR, Piacentino V, and Weisser J. Abnormalities of calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 32: 1595-1607, 2000.
24. 2+ ATPase modifies the transition from hypertrophy to early heart failure. Circ Res 89: 422-429, 2001.
25. Jasmin G, Solymoss B, and Proschek L. Therapeutic trials in hamster dystrophy. Ann NY Acad Sci 317: 338-348, 1979.
26. Just H. Pathophysiological targets for β-blocker therapy in congestive heart failure. Eur Heart J 17, Suppl B: 2-7, 1996.
27. Kimura J, Miyamae S, and Noma A. Identification of sodium-calcium exchange current in single ventricular cells of guinea pig. J Physiol 384: 199-222, 1987.
28. Kubo H, Margulies KB, Piacentino V, Gaughan J, and Houser SR. Patients with end-stage congestive heart failure treated with β-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 104: 1012-1018, 2001.
29. Lehnart SE, Schillinger W, Pieske B, Prestle J, Just H, and Hasenfuss G. Sarcoplasmic reticulum proteins in heart failure. Ann NY Acad Sci 853: 220-230, 1998.
30. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, and Dorn GW. Early and delayed consequences of β-adrenergic receptor overexpression in mouse hearts. Circulation 101: 1707-1714, 2000.
31. Lowes BD, Gilbert EM, Abraham WT, Minbobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, and Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 346: 1357-1365, 2002.
32. 2+ channel in mouse ventricular myocytes. Am J Physiol Heart Circ Physiol 272: H606-H612, 1997.
33. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 87: 731-738, 2000.
34. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, and Olson EN. A calcineurin-dependent transcriptional pathway from cardiac hypertrophy. Cell 93: 215-228, 1998.
35. Ouadid H, Albat B, and Nargeot J. Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 25: 282-291, 1995.
36. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, and Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349-1355, 1996.
37. 2+ content in isolated failing and nonfailing human myocardium. Circ Res 85: 38-46, 1999.
38. Reiken S, Gaburjakova M, Gaburjakova J, He K, Prieto A, Becker E, Yi G, Wang J, Burkhoff D, and Marks AR. β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104: 2843-2848, 2001.
39. Sabbah HN, Shimoyama H, Kono T, Gupta R, Sharov V, Scicli G, Levine B, and Goldstein S. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
40. 2+ content. Am J Physiol Cell Physiol 273: C1666-C1672, 1997.
41. 2+ exchanger. Circ Res 87: 581-587, 2000.
42. 2+ transients in failing human myocardium assessed with ryanodine. J Mol Cell Cardiol 30: 1285-1294, 1998.
43. Schmidt U, Hajjar RJ, Helm PA, Kim CS, Doye AA, and Gwathmey JK. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. J Mol Cell Cardiol 30: 1929-1937, 1998.
44. Schroder F, Handrock R, Beuckelmann DJ, Hirt S, Hullin R, Priebe L, Schwinger RH, Weil J, and Herzig S. Increased availability and open probability of single L-type calcium channel from failing compared with nonfailing human ventricle. Circulation 98: 969-976, 1998.
45. Sussman MA, Welch S, Cambon N, Klevitsky R, Hewett TE, Price R, Witt SA, and Kimball TR. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy injuvenile mice. J Clin Invest 101: 51-61, 1998.
46. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 90: 927-935, 1992.
47. Takeo S, Elmoselhi AB, Goel R, Sentex E, Wang J, and Dhalla NS. Attenuation of changes in sarcoplasmic reticular gene expression in cardiac hypertrophy by propranolol and verapamil. Mol Cell Biochem 213: 111-118, 2000.
48. 2+-ATPase in ventricular myocytes from transgenic mice. Cardiovasc Res 49: 38-47, 2001.
49. Tominaga M, Matsumori A, Okada I, Yamada T, and Kawai C. β-Blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation 83: 2021-2028, 1991.
50. Trépanier-Boulay V, St-Michel C, Tremblay A, and Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circ Res 89: 437-444, 2001.
51. Waagstein F, Caidahl K, Wallentin I, Bergh CH, and Hjalmarson A. Long-term β-blockage in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551-563, 1989.
52. Waagstein F, Hjalmarson A, Varnauskas E, and Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022-1036, 1975.
53. i transients in murine ventricular myocytes. Circ Res 82: 657-665, 1998.